August 19, 2023 at 2:15 p.m. | Read in 2 minutes
“The best report Benzinga has ever produced”
Huge returns are possible within this market! For a limited time, access the Benzinga Insider Report, normally $47 per month, for just $0.99. Discover the most undervalued stocks before their stocks skyrocket! Time is running out! Act now and secure your future wealth with this incredible discount! Claim your $0.99 offer now!
advertising article
OptimEyes.AI launches first-ever SEC Cybersecurity Readiness Program in response to SEC rules addressing cybersecurity governance and incident disclosure requirements for public companies.
SAN DIEGO, Aug. 19, 2023 /PRNewswire-PRWeb/ — OptimEyes.AI (RiskOpsAI™ by OptimEyes) Redefines Cyber and Enterprise Risk Management and Pioneers AI/ML-Driven Integrated Risk Modeling and Decision Making launches first SEC cybersecurity response program to address SEC rules addressing cybersecurity governance and disclosure requirements for incidents in publicly traded companies.
Enter to win $500 in stock or cryptocurrency
Enter your email to get the ultimate Benzinga morning update, a free $30 gift card and more.
AJ Sarkar said, “We are well positioned to help organizations navigate the new SEC disclosure requirements. Our capabilities will benefit any organization by enhancing their current cyber risk management programs. can bring,” he said. [by reducing] The touchpoints and skills needed to generate meaningful analytics. ”
Addressing SEC Cybersecurity with OptimEyes CTEM (Continuous Threat Exposure Management)
CTEM Redefines Cybersecurity Risk Management by Leveraging and Enriching Risk Data from Multiple Sources, Prepares Organizations for SEC Cybersecurity Rules, and Enhances Board Oversight of Cybersecurity Risk Management Program There is a possibility. This automated, AI/ML-driven, intelligent approach includes continuous risk assessment, risk quantification, and risk prioritization, including scenario planning.
CTEM helps organizations manage the target speed and intensity of advanced persistent threats (APTs), advanced malware (ransomware), and other forms of data intrusion and potential loss. CTEM proactively identifies threat scenarios that exceed an organization’s critical breach thresholds, enabling the board to more proactively manage their occurrence.
AJ Sarkar, Founder and CEO of OptimEyes, said, “We are well positioned to help organizations review their existing cyber risk governance arrangements and prepare for new SEC disclosure requirements. Every organization can benefit from a stronger cyber risk management program.” With his AI/ML-enhanced data in OptimEyes, there are fewer human touchpoints and fewer skills needed to generate meaningful analytics. ”
Secure your financial future
This market is waiting for you to find hidden gems! Don’t miss the Benzinga Insider Report. Normally $47 per month, now only $0.99. Discover these incredibly undervalued stocks before they skyrocket! Limited time offer! Ensure your financial success with this unmatched discount! Get your 0.99 offer now!
advertising article
About OptimEyes.ai
Based in San Diego, OptimEyes.ai is the pioneer of AI-driven RiskOps SaaS platform, providing integrated risk modeling and decision making. Built by his CXO of a Fortune 500 company with a deep background in cyber, risk and compliance, our Software-as-a-Service platform enables Fortune 2000 companies to address cyber, data privacy, ESG, compliance and enterprise risk. Please contact us for more information. https://optimeeyes.ai,follow me twitter and LinkedIn.
media contact
Andrew Beagley, OptimEyes.AI, 1 1 718 496 8635, andrewb@optimeyes.ai, www.optimeeyes.ai
Source OptimEyes.AI
“The best report Benzinga has ever produced”
Huge returns are possible within this market! For a limited time, access the Benzinga Insider Report, normally $47 per month, for just $0.99. Discover the most undervalued stocks before their stocks skyrocket! Time is running out! Act now and secure your future wealth with this incredible discount! Claim your $0.99 offer now!
advertising article
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.